Financial TimesEN
FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
Summit’s Ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US
🇬🇧 United Kingdom / English
The world, in perspective.
Fresh headlines from around the world. Gaming, politics, technology and everything in between.
HeiseDE
heise+ | Seltene Erden und Lithium: Wie Biotechnologie das Metallrecycling verändert
Europa forscht an neuen Verfahren, um mit Mikroorganismen, metallbindenden Molekülen und Wasserstoff wertvolle Rohstoffe aus Elektroschrott zu recyceln.
CNBCEN
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
The HinduEN
Bharat Biotech arm Nucelion to collaborate with Pandorum Tech on two PRIP-backed projects
Focus of the two ophthalmology projects will be on developing investigational therapies for advanced keratopathy and wet age-related macular degeneration
CNBCEN
Biotech stocks are surging. How investors can play the new drug innovation boom
Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.
Taipei TimesEN
US moots curbs on funds to Chinese biotech firms
TechCrunchEN
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
Allnira republishes accessible articles under owner-declared permissions, with original authors, publishers and image credits. Automatic cloud imports run hourly; open pages check for updates every 15 seconds. Publication delays depend on each feed.